الفهرس 
introductionOnly 14 pages are availabe for public view
 |  | from | 170 |  |  |
| | | from | 170 | | |
Abstract
Polycystic ovarian syndrome is the most frequent cause of anovulatory infertility and hyperandrogenism in young women. (franks , 1995)
Anti-Mullerian hormone (AMH), also termed Mullerian inhibiting substance, is a member of the tumor growth factor super family that also includes the granulosa cells (GC) and theca cell-derived inhibins and activins as well as the oocyte-derived growth differentiation factor nine. Although the roles of inhibins, activins, and growth differentiation factor nine on ovarian folliculogenesis have been extensively described, data about the role of AMH are still scarce. In the ovary, AMH is produced by the GC from preantral and small antral follicles. (Durlinger et al, 2002)
The serum AMH status has been less investigated in situations of folliclular excess. High levels of AMH were reported in the follicular fluid (Fallat et al., 1997) and in the serum of patients with PCOS (Cook et al., 2002), but these studies did not examine the relationship between AMH and the follicular number.
The aim of the present study was to assess the increase of serum AMH in patients with PCOS, as well as to relate the AMH level to the severity of manifestations, and finally to monitor the outcome of ovulation induction in terms of ovulation rate and conception rate and correlate them to AMH level.